



November 24, 2025

Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.

Novo Nordisk Inc. has recalculated its 340B ceiling prices for the period of 1Q2023 through 2Q2023 for the products listed below due to revisions made to its Medicaid pricing data. Novo Nordisk Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Novo Nordisk Inc.'s recalculation affecting certain 340B Covered Entities for the impacted products.

Novo Nordisk Inc. has determined the credit amount owed to each affected Covered Entity. Novo Nordisk Inc will be coordinating with its wholesalers to issue refunds to each affected Covered Entity. Refunds will be issued to a Covered Entity's validated wholesaler pharmacy account when one can be identified.

NDC	Product Description	340B Period
00169-4303-13	RYBELSUS 3MG 3X10 TABLETS	1Q2023-2Q2023
00169-4303-30	RYBELSUS 3MG TAB BOTTLE	1Q2023-2Q2023
00169-4307-13	RYBELSUS 7MG 3X10 TABLETS	1Q2023-2Q2023
00169-4307-30	RYBELSUS 7MG TAB BOTTLE	1Q2023-2Q2023
00169-4314-13	RYBELSUS 14MG 3X10 TABLETS	1Q2023-2Q2023
00169-4314-30	RYBELSUS 14MG TAB BOTTLE	1Q2023-2Q2023
00169-4130-13	OZEMPIC 1MG 1X3ML 4PCS.NFPL	1Q2023-2Q2023
00169-4772-12	OZEMPIC 2MG 1X3ML 4PCS.NFPL	1Q2023-2Q2023

If a Covered Entity believes it is due a refund and has not seen a credit to its wholesaler account by January 16, 2026, it may contact Novo Nordisk Inc., at NNIBIDNOTIFICATION@novonordisk.com.